Abstract
Chitosan is widely used in ocular drug delivery systems due to its biocompatibility, biodegradability, and favorable physicochemical characteristics. Chitosan-based ocular drug delivery systems are widely reported to improve the bioavailability at the anterior/posterior pole of the eye due to its mucoadhesive property that helps to increase efficacy of existing ocular drugs, affords stimuli responsive/targeted-based delivery regimen, enhances the corneal permeability, and improves the accumulation of drugs in the corneal/conjunctival epithelia for an extended period of time. This review summarizes the major ocular diseases affecting the eye, ocular delivery systems, novel ocular drug delivery systems, intraocular drug transport barriers, and ocular transporters. The utilization of chitosan toward the ocular drug delivery systems such as stimuli responsive systems, targeted delivery systems, and gene-based delivery systems is also discussed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- AMD:
-
Age-related macular degeneration
- BBS:
-
Bardet-Biedl syndrome
- CS:
-
Chitosan
- CS-NP:
-
Chitosan nanoparticle
- JNK:
-
C-jun NH2 terminal kinase
- CSL-NPs:
-
Core-shell liponanoparticles
- CMV:
-
Cytomegalovirus
- DR:
-
Diabetic retinopathy
- DAG:
-
Diacylglycerol
- DES:
-
Diethyl squarate
- EPR:
-
Enhanced permeability and retention effect
- EGDE:
-
Ethylene glycol diglycidyl ether
- HA:
-
Hyaluronan
- LCA:
-
Leber congenital amaurosis
- LCA2:
-
Leber congenital amaurosis type 2
- LCST:
-
Lower critical solution temperature
- NPs:
-
Nanoparticles
- NF- κB:
-
Nuclear factor-kappa B
- PLGA:
-
Poly(lactic-co-glycolic acid)
- PARP:
-
Poly(adenosine diphosphate-ribose) polymerase-1
- PEG:
-
Polyethylene glycol
- PKC:
-
Protein kinase C
- QUR:
-
Quercetin
- RAS:
-
Renin-angiotensin-aldosterone system
- RES:
-
Resveratrol
- RP:
-
Retinitis pigmentosa
- RPE:
-
Retinal pigment epithelium
- ROCK:
-
Rho-associated protein kinase
- SEM:
-
Scanning electron microscopy
- SARM:
-
Selective androgen receptor modulators
- SERM:
-
Selective estrogen receptor modulators
- SNP:
-
Self-assembled nanoparticles
- TDDS:
-
Targeted drug delivery system
- VEGF:
-
Vascular endothelial growth factor
References
Agarwal R, Gupta SK, Agarwal P, Saxena R, Agrawal SS (2009) Current concepts in the pathophysiology of glaucoma. Indian J Ophthalmol 57(4):257–266
Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2(10):750–763. https://doi.org/10.1038/nrc903
Bennet BL, Sasaki DT, Murray BW et al (2001) SP600125. An anthrapyrazolone inhibitor of Jun N- terminal kinase. Proc Nat Acad Sci USA 98:13681–13686
Berger J, Reist M, Mayer JM, Felt O, Peppas NA, Gurny R (2004) Structure and interactions in covalently and ionically crosslinked chitosan hydrogels for biomedical applications. Eur J Pharm Biopharm 57(1):19–34. https://doi.org/10.1016/S0939-6411(03)00161-9
Bhattarai N, Gunn J, Zhang M (2010) Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev 62(1):83–99. https://doi.org/10.1016/j.addr.2009.07.019
Bowman LM, Si E, Pang J, Archibald R, Friedlaender M (2009) Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. J Ocul Pharmacol Ther 25(2):133–139
Chaira G, Zeina D, Paola S et al (2009) The TGF-β pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes 58:1659–1667
Chawla SP, Kanatt SR, Sharma AK (2014) Chitosan. In: Ramawat KG, Mérillon J (eds) Polysaccharides bioactivity and biotechnology. Springer, Cham, pp 219–246
Cheng Y, Hung K, Tsai T, Lee C (2014) Sustained delivery of latanoprost by thermosensitive chitosan-gelatin-based hydrogel for controlling ocular hypertension. Acta Biomater. https://doi.org/10.1016/j.actbio.2014.05.031
Cheng Y, Tsai T, Jhan Y, Chiu AW, Tsai K, Chien C et al (2016a) Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment. Carbohydr Polym 144:390–399. https://doi.org/10.1016/j.carbpol.2016.02.080
Cheng YH, Tsai TH, Jhanb YY, Chiud AW h, Tsai KL, Chien CS, Chioub SH, Liu CJ l (2016b) Thermosensitive chitosan-based hydrogel as a topical ocular drug delivery system of latanoprost for glaucoma treatment. Carbohydr Polym 144
Chiou GCY (2001) Review: effects of nitric oxide on eye diseases and their treatment. J Ocul Pharmacol Ther 17(2):189–198. https://doi.org/10.1089/10807680151125555
Colligris B, Alkozi HA, Pintor J (2014) Recent developments on dry eye disease treatment compounds. Saudi J Ophthalmol 28(1):19–30. https://doi.org/10.1016/j.sjopt.2013.12.003
Conley SM, Naash MI (2010) Progress in retinal and eye research nanoparticles for retinal gene therapy. Prog Retin Eye Res 29(5):376–397. https://doi.org/10.1016/j.preteyeres.2010.04.004
Contreras-Ruiz L, de la Fuente M, García-Vázquez C, Sáez V, Seijo B, Alonso MJ, Calonge M, Diebold Y (2010) Ocular tolerance to a topical formulation of hyaluronic acid and chitosan-based nanoparticles. Cornea 29(5):550–558
Dalton JT, Miller DD, Rakov I et al (2008) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof. Patent application no. PCT/US2007/016311
Davis BM, Pahlitzsch M, Guo L, Balendra S, Shah P, Ravindran N, et al (2018) Topical curcumin nanocarriers are neuroprotective in eye disease. Sci Reps March: 1–13. https://doi.org/10.1038/s41598-018-29393-8
De M, Raviña M, Paolicelli P, Sanchez A, Seijo B, Jose M (2010) Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev 62(1):100–117. https://doi.org/10.1016/j.addr.2009.11.026
Delgado D, Pozo-rodríguez A, Solinís MA, Bartkowiak A, Rodríguez-gascón A (2013) European Journal of Pharmaceutical Sciences New gene delivery system based on oligochitosan and solid lipid nanoparticles : ‘ In vitro ’ and ‘ in vivo ’ evaluation. Eur J Pharm Sci 50(3–4):484–491. https://doi.org/10.1016/j.ejps.2013.08.013
Deng H, Wang Y, Ding Q, Li D, Wei Y (2017) Gene therapy research in Asia 1:572–577. https://doi.org/10.1038/gt.2017.62
Diebold Y, Calonge M (2010) Progress in retinal and eye research applications of nanoparticles in ophthalmology. Prog Retin Eye Res 29(6):596–609. https://doi.org/10.1016/j.preteyeres.2010.08.002
Dubald M, Bourgeois S, Andrieu V, Fessi H (2018) Ophthalmic drug delivery systems for antibiotherapy-a review. https://doi.org/10.3390/pharmaceutics10010010
Elsaid N, Jackson TL, Elsaid Z, Alqathama A, Somavarapu S (2016) Article PLGA microparticles entrapping chitosan-based nanoparticles for the ocular delivery of ranibizumab. https://doi.org/10.1021/acs.molpharmaceut.6b00335
Gan L, Wang J, Zhao Y, Chen D, Zhu C, Liu J, Gan Y (2013) Biomaterials Hyaluronan-modified core e shell liponanoparticles targeting CD44- positive retinal pigment epithelium cells via intravitreal injection. Biomaterials 34(24):5978–5987. https://doi.org/10.1016/j.biomaterials.2013.04.035
Ginn SL, Amaya AK, Abedi MR, Alexander IE, Edelstein M (2018). Gene therapy clinical trials worldwide to 2017: an update, (February): 1–16. https://doi.org/10.1002/jgm.3015
Gratieri T, Martins G, Melani E, Hugo V, De Freitas O, Fonseca R, Lopez V (2010) European Journal of Pharmaceutics and Biopharmaceutics A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm 75(2):186–193. https://doi.org/10.1016/j.ejpb.2010.02.011
Gratieri T, Martins G, Freitas O De, Melani E, Lopez RFV (2011) European Journal of Pharmaceutics and Biopharmaceutics Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer / chitosan in situ forming gel 79:320–327. https://doi.org/10.1016/j.ejpb.2011.05.006
Guo C, Qu X, Rangaswamy N, Leehy B, Xiang C, Rice D et al (2018) A murine glaucoma model induced by rapid in vivo photopolymerization of hyaluronic acid glycidyl methacrylate. PLoS ONE 13(6):e0196529
Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A (2015) Levofloxacin eye drops for prolong ocular retention 7(1): 9–14. https://doi.org/10.4103/0975-7406.149810
Hanna E, Rémuzat C, Auquier P, Toumi M (2017) Gene therapies development: slow progress and promising prospect. J Mark Access Health Policy 00(00):1–9. https://doi.org/10.1080/20016689.2017.1265293
Harikumar SL, Sonia A (2011) Available online http://www.ijddr.in Covered in Official Product of Elsevier, The Netherlands © 2010 IJDDR Nanotechnological approaches in Ophthalmic delivery systems 3(4):9–19
Hennink WE, van Nostrum CF (2002) Novel crosslinking methods to design hydrogels. Adv Drug Deliv Rev 54:13–36
Hsiao F, Huang P, Aoyagi T, Chang S (2017) ScienceDirect In vitro and in vivo assessment of delivery of hydrophobic molecules and plasmid DNAs with PEO e PPO e PEO polymeric micelles on cornea. J Food Drug Anal:1–10. https://doi.org/10.1016/j.jfda.2017.09.002
Jee D, Kang S, Yuan C, Cho E, Arroyo JG, The Epidemiologic Survey Committee of the Korean Ophthalmologic Society (2016) Serum 25-hydroxyvitamin D levels and dry eye syndrome: differential effects of vitamin D on ocular diseases. PLoS ONE 11(2):e0149294
Jiang S, Franco YL, Zhou Y, Chen J (2018) Nanotechnology in retinal drug delivery. Int J Ophthalmol. https://doi.org/10.18240/ijo.2018.06.23
Kalam MA (2016) The potential application of hyaluronic acid coated chitosan nanoparticles in ocular delivery of dexamethasone. Int J Biol Macromol. https://doi.org/10.1016/j.ijbiomac.2016.05.016
Kean T, Thanou M (2010) Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 62(1):3–11. https://doi.org/10.1016/j.addr.2009.09.004
Kirchhof S, Gopeferich AM, Brandl FP (2015) European Journal of Pharmaceutics and Biopharmaceutics Hydrogels in ophthalmic applications. Eur J Pharm Biopharm June. https://doi.org/10.1016/j.ejpb.2015.05.016
Klausner EA, Zhang Z, Chapman RL, Multack RF, Volin MV (2010) Biomaterials Ultrapure chitosan oligomers as carriers for corneal gene transfer. Biomaterials 31(7):1814–1820. https://doi.org/10.1016/j.biomaterials.2009.10.031
Kompella UB, Amrite AC, Ravi RP, Durazo SA (2013) Progress in retinal and eye research nanomedicines for back of the eye drug delivery , gene delivery , and imaging. Prog Retin Eye Res. April. https://doi.org/10.1016/j.preteyeres.2013.04.001
Koo H, Moon H, Han H, Hee J, Sook M, Hyung J et al (2012) Biomaterials the movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials 33(12):3485–3493. https://doi.org/10.1016/j.biomaterials.2012.01.030
Liang H, Brignole-Baudouin F, Rabinovich-Guilatt L, Mao Z, Riancho L, Faure MO, Warnet JM, Lambert G, Baudouin C (2008) Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol Vis 14:204–216
Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z (2008) Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev 60(15):1650–1662. https://doi.org/10.1016/j.addr.2008.09.001
Ljubimov AV, Saghizadeh M (2015) Progress in Retinal and Eye Research Progress in corneal wound healing. Prog Retin Eye Res 49(June 2018):17–45. https://doi.org/10.1016/j.preteyeres.2015.07.002
Lopes CM, Barata P, Oliveira R (2018). Chapter 5. Stimuli-responsive nanosystems for drug-targeted delivery. Elsevier. https://doi.org/10.1016/B978-0-12-813689-8.00005-7
Mahlumba P, Choonara YE, Kumar P, Toit LC, Pillay V (2016) Stimuli-responsive polymeric systems for controlled protein and peptide delivery: future implications for ocular delivery. https://doi.org/10.3390/molecules21081002
Mohammed MA, Syeda JTM, Wasan KM, Wasan EK (2017) An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics 9(4):53. https://doi.org/10.3390/pharmaceutics9040053
Mohd IN, Marvan A, HHaseeb AK et al (2013) Novel drugs and their targets in the potential treatment of diabetic retinopathy. Med Sci Monit 19:300–308
Morris GA, Kök SM, Harding SE, Adams GG, Morris GA, Kök SM, et al (2013) Polysaccharide drug delivery systems based on pectin and chitosan Polysaccharide delivery systems systems Polysaccharide drug drug delivery based on pectin and chitosan based on pectin and chitosan. 8725. https://doi.org/10.1080/02648725.2010.10648153
Natesan S, Pandian S, Ponnusamy C, Palanichamy R, Muthusamy S, Kandasamy R (2017a) Co-encapsulated resveratrol and quercetin in chitosan and pegmodified chitosan nanoparticles: for efficient intra ocular pressure reduction. Int J Biol Macromol 104:1837–1845
Natesan S, Krishnaswami V, Radhakrishnan S, Kumar VS, Sonali S, Nirmal J, Gaye S (2017b) New drug targets and drug delivery strategies for various ocular disorders. Bio targets and drug delivery approaches. Taylor & Francis Group, pp 1–32
Otero-Espinar FJ, Fernandez-Ferreiro A, Gonzalez-Barcia M, Blanco-Mendez J, Luzardo A (2018) Drug targeting and stimuli sensitive drug delivery systems. Elsevier. Stimuli Sensitive Ocular Drug Delivery Systems 6. https://doi.org/10.1016/B978-0-12-813689-8.00006-9
Park JH, Saravanakumar G, Kim K, Chan I (2010) Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev 62(1):28–41. https://doi.org/10.1016/j.addr.2009.10.003
Patel PB, Shastri DH, Shelat PK, Shukla AK (2010) Ophthalmic drug delivery system: challenges and approaches. Syst Rev Pharm 1(2):113
Patel A, Cholkar K, Agrahari V, Mitra AK (2013) Ocular drug delivery systems: an overview. World J Pharmacol 2(2):47–64
Pollreisz A, Schmidt Erfurth U (2010) Diabetic cataract pathogenesis, epidemiology and treatment. J Ophthalmol 608751
Puras G, Zarate J, Aceves M, Murua A, Díaz AR, Avilés-triguero M, Fernández E (2013a) European Journal of Pharmaceutics and Biopharmaceutics Low molecular weight oligochitosans for non-viral retinal gene therapy. Eur J Pharm Biopharm 83(2):131–140. https://doi.org/10.1016/j.ejpb.2012.09.010
Puras G, Zarate J, Díaz-tahoces A, Avilés-trigueros M, Fernández E, Pedraz JL (2013b) European Journal of Pharmaceutical Sciences Oligochitosan polyplexes as carriers for retinal gene delivery. Eur J Pharm Sci 48(1–2):323–331. https://doi.org/10.1016/j.ejps.2012.11.009
Ratemi E (2018) pH-responsive polymers for drug delivery applications. Stimuli Responsive Polymeric Nanocarriers for Drug Delivery Applications, Volume 1. Elsevier. https://doi.org/10.1016/B978-0-08-101997-9.00005-9
Richard J, Callaghan O (2018) The pathogenesis of staphylococcus aureus eye infections. Pathogens 7(9):1–22
Sen KK, Maiti S (2017) Basic concept in drug targeting. Bio targets and drug delivery approaches. Taylor & Francis Group, pp 1–32
Shi S, Zhang Z, Luo Z, Yu J, Liang R, Li X, Chen H (2015) Chitosan grafted methoxy poly (ethylene glycol) -poly (ε – caprolactone) nanosuspension for ocular delivery of hydrophobic diclofenac. Nature Publishing Group, (June), pp 1–12. https://doi.org/10.1038/srep11337
Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK (2010) NIH Public Access 16(5):645–659. https://doi.org/10.1038/gt.2008.185.Intravenous
Solinís MÁ, Pozo-rodríguez A, Apaolaza PS (2014) Treatment of ocular disorders by gene therapy. Eur J Pharm Biopharm. https://doi.org/10.1016/j.ejpb.2014.12.022
Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R (2013) Pathophysiology of diabetic retinopathy. ISRN Ophthalmol:1–3
Tsai CY, Woung LC, Yen JC, Tseng PC, Chiou SH, Sung YJ et al (2016) Thermosensitive chitosan-based hydrogels for sustained release of ferulic acid on corneal wound healing. Carbohydr Polym 135:308–315. https://doi.org/10.1016/j.carbpol.2015.08.098
Vellonen KS, Pelkonen L, Mannermaa E, Ruponen M, Urtti A, Kidron H (2017) Expression, activity and pharmacokinetic impact of ocular transporters. Adv Drug Deliv Rev
Wadhwa S, Paliwal R, Rai Paliwal S, Vyas SP (2009) Chitosan and its role in ocular therapeutics. Mini Rev Med Chem 9(14):1639–1647. https://doi.org/10.2174/138955709791012292
Weng Y, Liu J, Jin S, Guo W (2016) Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm Sin B:1–11. https://doi.org/10.1016/j.apsb.2016.09.001
Wu Y, Liu Y, Li X, Kebebe D, Zhang B, Ren J et al (2018) Research progress of in-situ gelling ophthalmic drug delivery system. Asian J Pharm Sci 000:1–15. https://doi.org/10.1016/j.ajps.2018.04.008
Xu Q et al (2013) Nanotechnology approaches for ocular drug delivery. Middle East African J Ophthalmol 20(1):26–37
Yoo JW, Irvine DJ, Discher DE, Mitragotri S (2011) Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 10(7):521–535. https://doi.org/10.1038/nrd3499
Yuan X (2006) Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface 65:337–345. https://doi.org/10.1016/j.carbpol.2006.01.020
Zhou R, Caspi RR (2010) Ocular immune privilege 3(January): 1–3. https://doi.org/10.3410/B2-3
Zulliger R, Conley SM, Naash MI (2015) Non-viral therapeutic approaches to ocular diseases: An overview and future directions. J Control Release. https://doi.org/10.1016/j.jconrel.2015.10.007
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Natesan, S., Krishnaswami, V., Thekkila Veedu, S., Pathayappurakkal Mohanan, D., Ruckmani, K., Palanichamy, R. (2019). Chitosan-Based Ocular Drug Delivery Systems. In: Jana, S., Jana, S. (eds) Functional Chitosan. Springer, Singapore. https://doi.org/10.1007/978-981-15-0263-7_4
Download citation
DOI: https://doi.org/10.1007/978-981-15-0263-7_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-0262-0
Online ISBN: 978-981-15-0263-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)